ANGIOSARCOMA

This study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. The goal is to see if adding the targeted drug pazopanib (and another drug, selinexor, for high-risk patients) to standard chemotherapy and radiation can…

This early-phase study tests a new drug called AGX101 in people with advanced solid tumors that have not responded to standard treatments. AGX101 is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find the safest dose and to check for sid…

This study is for people with bone sarcomas who have finished their first round of treatment. It tests whether taking the drug regorafenib for up to 12 months can help keep the cancer from returning, compared to just being watched. About 168 participants will be randomly assigned…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy can help shrink or control advanced soft tissue sarcomas that cannot be removed by surgery. About 45 adults aged 18-75 with certain sarcoma types will receive the combination as their fir…

This study follows 250 people diagnosed with localized angiosarcoma, a rare cancer of the blood vessels. Researchers will collect information on patient characteristics, tumor features, and treatments used in everyday practice. The goal is to learn more about the disease and impr…

This study is testing whether adding new experimental drugs to standard chemotherapy before surgery can improve outcomes for people with breast cancer. It includes up to 5,000 participants with early-stage or locally advanced breast cancer. The goal is to use MRI scans and tissue…

This study is gathering tissue samples and medical information from 800 people with high-risk soft tissue sarcomas. The goal is to learn how to personalize chemotherapy before surgery, using genetic and protein profiles. Participants either receive standard chemo plus surgery or …